These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17225281)

  • 41. Immune-based therapies at the retrovirus conference.
    Raymond D
    Posit Aware; 2003; 14(3):16-7. PubMed ID: 12866485
    [No Abstract]   [Full Text] [Related]  

  • 42. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-HIV agents. Viral load blips linked to adherence.
    TreatmentUpdate; 2008 Jan; 20(1):4-6. PubMed ID: 18323003
    [No Abstract]   [Full Text] [Related]  

  • 44. [HIV eradication--facts and fiction].
    Jaeger H; Wolf E
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
    [No Abstract]   [Full Text] [Related]  

  • 45. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significant differences in DNA viral load between HIV-1 and HIV-2 infected patients.
    Gueudin M; Bénard A; Chêne G; Matheron S; Simon F
    AIDS; 2008 Jul; 22(12):1519-20. PubMed ID: 18614877
    [No Abstract]   [Full Text] [Related]  

  • 47. Antiretroviral treatment during pregnancy.
    Keiser O; Gayet-Ageron A; Rudin C; Brinkhof MW; Gremlich E; Wunder D; Drack G; Hirschel B; de Tejada BM; ;
    AIDS; 2008 Nov; 22(17):2323-30. PubMed ID: 18981771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
    Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
    J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploring how to get at--and eradicate--hidden HIV.
    Cohen J
    Science; 1998 Mar; 279(5358):1854-5. PubMed ID: 9537902
    [No Abstract]   [Full Text] [Related]  

  • 50. Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children.
    Miziara ID; Weber R
    J Oral Pathol Med; 2008 Feb; 37(2):99-106. PubMed ID: 18197855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes of a trial of HIV-1 immunogen in patients with HIV infection.
    Dat NV
    JAMA; 2001 May; 285(17):2191; 2193-5. PubMed ID: 11325312
    [No Abstract]   [Full Text] [Related]  

  • 52. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination against drug resistance in HIV infection.
    Boberg A; Isaguliants M
    Expert Rev Vaccines; 2008 Feb; 7(1):131-45. PubMed ID: 18251699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Failed HIV vaccine may have increased vulnerability to infection.
    Clin Infect Dis; 2008 Jan; 46(1):iii. PubMed ID: 18181273
    [No Abstract]   [Full Text] [Related]  

  • 56. Update from Seattle: the 9th Annual Retrovirus Conference.
    Laurence J
    AIDS Read; 2002 Apr; 12(4):132-3, 141. PubMed ID: 12071181
    [No Abstract]   [Full Text] [Related]  

  • 57. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
    AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
    J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Large US study of HIV vaccine is halted because of lack of efficacy.
    McCarthy M
    BMJ; 2013 Apr; 346():f2734. PubMed ID: 23628751
    [No Abstract]   [Full Text] [Related]  

  • 60. Keeping hope alive: HIV vaccines & the community.
    Montecalvo M
    Body Posit; 2004; 17(4):15-6. PubMed ID: 15929209
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.